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 Letter to the Editor  
“ONE SIZE WON’T FIT ALL” 
Response to: In-Depth Evaluation of the AJCC 2010 Staging System 
for Luminal-like Breast Cancer-An Analysis from a Free-Standing 
Cancer Hospital 
Brian P. Hung* 
Department of General Surgery, Cardinal Tien Hospital, New Taipei City, Taiwan  
I find it very interesting in reading the article of 
“In-Depth Evaluation of the AJCC 2010 Staging Sys-
tem for Luminal-like Breast Cancer-An Analysis from 
a Free-Standing Cancer Hospital.” by Cheng, Skye 
HC, et al. [1] Prior to the era of molecular biology age, 
anatomically-based TNM staging system is the only 
and the best parameter of the prognostic value in the 
field of management of the solid tumor. To use bio-
logical nature to exam and to correlate to the anatomic 
abnormalities may not always be resulted in sound 
conclusion yet it may bring up some important ques-
tions of different aspects between biology and anato-
my [2]. 
The primary tumor size used in figure 2 and the 
five-year BCSR of three different groups (T,N) in ta-
ble 3 were different from those data in AJCC, 7th edi-
tion, 2010 [2]. Thus, it would be very difficult for us 
to compare between them and subsequently to draw 
any reasonable definitive conclusions. 
There was no mention of the terminology of “Lu-
minal” in St. Gallen Consensus Conference until “Lu-
minal A and Luminal B” in 2011 [3] and “Luminal 
A-like and Luminal B-like” as clinico-pathologic sur-
rogate definition in 2013 [4]. In terms of the types of 
therapy for Luminal A-like, the conclusive statement 
is as follow : “Endocrine therapy is the most critical 
intervention and is often used alone. Cytotoxics may 
be added in selected patients.…….” [3,4]. However, 
this is quite contrary to the view expressed in the sec-
tion of the discussion of the article [1]. 
Although the current TNM anatomically-based 
staging system is not perfect yet the questions of 1. 
Does biology matter and 2. Can it trump anatomy? 
remained to be answered [5]. For these critical im-
portant issues we may need more data available to us 
in order to be able to delineate further in the near fu-
ture. 
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